4-Methoxy-E1 is an estrogen metabolite formed by the enzyme catechol-O-methyltransferase (COMT) from 4-hydroxyestrone, a process that significantly reduces its potential to cause DNA damage by preventing the formation of reactive quinone species.
Unlike its precursor 4-hydroxyestrone, 4-Methoxy-E1 is a safer byproduct in estrogen metabolism. This conversion is a critical aspect of estrogen detoxification, primarily occurring in the liver and adipose tissues, which play significant roles in steroid metabolism.
The ratio of 4-Methoxy-E1 to 4-hydroxyestrone serves as a crucial biomarker for assessing methylation efficiency and related cancer risks, with imbalances possibly indicating an increased likelihood of breast cancer due to inadequate methylation.
Understanding and monitoring levels of 4-Methoxy-E1 through urinary testing can help in maintaining hormonal balance and reducing health risks, especially in hormone-sensitive tissues.
4-Methoxy-E1 is a metabolite derived from the methylation of 4-hydroxyestrone, facilitated by the enzyme catechol-O-methyltransferase (COMT), as part of phase 2 estrogen detoxification.
Structurally similar to estrone, this 4-Methoxy-E1 is distinguished by the replacement of a hydrogen atom at position 4 with a methoxy group.
It is considered a neutralized version of the potentially carcinogenic 4-hydroxyestrone, as the methylation by COMT makes it less likely to oxidize and form reactive quinone species that can cause DNA damage.
This metabolite is involved in complex biochemical pathways, highlighting its role in reducing the genotoxic effects of estrogen metabolism.
The metabolic pathway of 4-Methoxy-E1 occurs in multiple organs including the liver and adipose tissues, which are critical sites for steroid metabolism and storage.
The ratio of 4-Methoxy-E1 to 4-hydroxyestrone is used as a biomarker to assess methylation efficiency and the associated cancer risk.
Low levels of 4-MeOE1 in the presence of normal or high levels of 4-hydroxyestrone may indicate poor methylation capacity, which could be associated with an increased risk of breast cancer.
Maintaining adequate levels of cofactors and methyl donors, such as methionine, magnesium, B vitamins (B2, B6, B12), folic acid, and betaine (trimethylglycine), can support COMT activity and promote the methylation of 4-hydroxyestrone to 4-MeOE1.
Urine samples are commonly used for 4-Methoxy-E1 testing.
Estrogen metabolites can be excreted in the urine, making it a reliable method for testing estrogen detoxification and comparing ratios of estrogen metabolites. Urine testing specifically assesses phase I estrogen detoxification, and it can also be used to assess phase II methylation detoxification.
Urine collection can be easier and less stressful for patients compared to blood draws, as samples can be collected at home without the need for a clinical setting. Additionally, urinary levels can reflect longer-term hormone exposure rather than the transient levels often seen in blood, as it reflects detoxification patterns (rather than providing snapshots of levels in the bloodstream).
It is important to consult with the lab company providing testing for 4-Methoxy-E1 levels. For reference, one lab provides the following reference range for urine 4-Methoxy-E1 levels: [9.]
0.007-0.05 ng/mg creatinine/day
Hormones never act alone, and their effects are nuanced. Optimal levels of 4-Methoxy-E1 in urine tests vary depending on individual health conditions, gender, and age. As a methylated metabolite of estrogen, 4-Methoxy-E1 is still considered a preferred estrogen detoxification pathway.
One recommendation is that 60-80% of a woman's circulating estrogen utilize the 2-OH pathway; that 13-30% utilizes the 16-OH pathway; and that the remaining 7.5-11% utilizes the 4-OH pathway. [8.]
Health professionals often recommend that women remain within the reference range of 0.007-0.05 ng/mg creatinine/day in urine samples. However, a professional's recommendation will be affected by many factors including the patient’s overall health, detoxification capacity, personal and family health history, time of life, diet and lifestyle, medications, and other factors.
Regular monitoring through urinary tests is essential to ensure that estrogen metabolite levels are within a safe range, thereby reducing the potential for DNA damage and promoting better hormonal balance and overall health.
In postmenopausal women receiving hormone replacement therapy, elevated levels of 4-Methoxy-E1 may indicate an excessive amount of hormone supplementation which may be causing unwanted overstimulation of estrogen-sensitive tissue at the breasts and endometrium.
These women should have their dosages assessed by a healthcare professional, and estrogen detoxification support may be considered.
Premenopausal women with elevated levels of 4-Methoxy-E1 should be assessed by a healthcare professional, including a comprehensive assessment of male and female sex hormones, as well as considering adrenal and thyroid hormone levels. Additionally, estrogen detoxification support may be considered.
Premenopausal women, or women supplementing with estrogen who complain of estrogen excess symptoms, should be assessed for estrogen and estrogen metabolite levels.
See below for more information on natural methods to promote hormone balance.
Typically, declining levels of estrogen and its metabolites are seen postmenopausally. Testing of estrogen metabolites may be recommended for women complaining of menopausal symptoms.
Additionally, postmenopausal women with a family or personal history of osteoporosis or low bone mineral density should consider testing their estrogen and estrogen metabolite levels.
Several other biomarkers are associated with estrogen metabolism and activity. Other estrogen metabolites including2-hydroxyestrone (2-OH-E1), 16-hydroxyestrone (16-OH-E1) and 4-hydroxyestrone (4-hydroxyestrone), as well as estrone (E1), estradiol (E2), and estriol (E3) levels should be considered.
2-OH estrone is a direct precursor in the metabolic pathway that leads to 2-Methoxyestrone, another methylated metabolite of estrone.
Evaluating both metabolites provides a more comprehensive view of estrogen metabolism, particularly in the 2-OH pathway, and helps in understanding the balance between estrogen metabolites that may influence cancer risk and other hormone-related conditions.
16-Hydroxyestrone (16-OH E1) is a metabolite of estrone, one of the three main naturally occurring estrogens in the human body.
Unlike some other estrogen metabolites, 16-OH E1 exhibits relatively strong estrogenic activities. It binds to estrogen receptors, potentially influencing estrogen-responsive gene expression and cellular functions.
This metabolite has been associated with various physiological effects and is implicated in different health conditions, including increased risks for certain types of cancers due to its potent estrogenic properties.
4-OH estrone is another metabolite of estrone with strong estrogenic properties and potential carcinogenic effects.
Specifically, 4-OH estrone is known for its potential to form quinones that can directly damage DNA and generate reactive oxygen species, increasing the risk of mutagenesis.
Measuring 4-OH estrone alongside 16-OH estrone and 4-Methoxy-E1 can help assess the overall estrogenic and carcinogenic potential within the body.
Estrone is a weaker estrogen compared to estradiol but is prevalent in postmenopausal women and can be converted back to estradiol.
Testing for estrone is important for understanding the overall estrogenic activity, especially in postmenopausal women who are at increased risk for estrogen-sensitive cancers.
Estradiol is the most potent estrogen and has significant implications for bone density, reproductive health, and cardiovascular health. Monitoring estradiol levels is essential for assessing reproductive health and menopausal status, and for managing hormone replacement therapy effectively.
Estriol is a weak estrogen predominantly produced during pregnancy. Outside of pregnancy, its levels are very low, but it has been suggested to have protective effects against breast cancer.
Testing for estriol, especially in non-pregnant states, might provide additional insights into estrogenic activity and potential protective mechanisms against estrogen-related pathologies.
It is always essential to work with a qualified healthcare professional in any case of hormone imbalance. The following diet and lifestyle measures have been shown to naturally promote healthy hormone balance:
Dietary Fiber Increase: consuming more fiber helps bind estrogen in the digestive tract, promoting its excretion and reducing reabsorption. [5.]
Interestingly, one study of 240 women also showed a correlation between increased fiber intake and anovulation, possibly due to lower estrogen levels. [5.]
Cruciferous Vegetables: foods like broccoli, cauliflower, and Brussels sprouts contain indole-3-carbinol, which aids in detoxifying excessive estrogen and optimizing hormone balance. [2.]
Regular Exercise: physical activity can help balance hormones by improving metabolism and reducing fat, which is significant since body fat can produce and store estrogen. [11.]
Probiotics and Gut Health: a healthy gut flora supports proper digestion and detoxification processes, including the breakdown, elimination and balance of hormones like estrogen. [6.]
Limit Alcohol and Caffeine: reducing intake of substances that can impair liver function helps ensure the liver effectively processes and removes excess hormones. [4., 10.]
Stress Management: stress may have an impact on estrogen levels and metabolism; techniques such as yoga, meditation, or even simple breathing exercises can reduce cortisol levels and help maintain a healthy hormonal balance. [1.]
Click here to explore testing options and order testing for 4-Methoxy-E1 levels.
[1.] Assad S, Khan HH, Ghazanfar H, Khan ZH, Mansoor S, Rahman MA, Khan GH, Zafar B, Tariq U, Malik SA. Role of Sex Hormone Levels and Psychological Stress in the Pathogenesis of Autoimmune Diseases. Cureus. 2017 Jun 5;9(6):e1315. doi: 10.7759/cureus.1315. PMID: 28690949; PMCID: PMC5498122.
[2.] Auborn KJ, Fan S, Rosen EM, et al. Indole-3-Carbinol Is a Negative Regulator of Estrogen. The Journal of Nutrition. 2003;133(7):2470S2475S. doi:https://doi.org/10.1093/jn/133.7.2470s
[3.] Cavalieri E, Chakravarti D, Guttenplan J, et al. Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2006;1766(1):63-78. doi:https://doi.org/10.1016/j.bbcan.2006.03.001
[4.] Emanuele MA, Wezeman F, Emanuele NV. Alcohol's effects on female reproductive function. Alcohol Res Health. 2002;26(4):274-81. PMID: 12875037; PMCID: PMC6676690.
[5.] Gaskins AJ, Mumford SL, Zhang C, et al. Effect of daily fiber intake on reproductive function: the BioCycle Study. The American Journal of Clinical Nutrition. 2009;90(4):1061-1069. doi:https://doi.org/10.3945/ajcn.2009.27990
[6.] Maeng LY, Beumer A. Never fear, the gut bacteria are here: Estrogen and gut microbiome-brain axis interactions in fear extinction. International Journal of Psychophysiology. 2023;189:66-75. doi:https://doi.org/10.1016/j.ijpsycho.2023.05.350
[7.] PubChem. 4-Methoxy-E1. pubchem.ncbi.nlm.nih.gov. Accessed May 10, 2024. https://pubchem.ncbi.nlm.nih.gov/compound/194066
[8.] Rupa Health. DUTCH Complete M+F Sample Report.pdf. Google Docs. Accessed April 27, 2024. https://drive.google.com/file/d/1-qmxwjo6B2TVYlgCS-FlcyF8FuqRdZEe/view
[9.] Rupa Health. Estrogen Metabolites Profile Sample Report.pdf. Google Docs. https://drive.google.com/file/d/1nEwGz74OzsPUDQTwjEnyAkWf-Zo3JZ_0/view
[10.] Sisti JS, Hankinson SE, Caporaso NE, Gu F, Tamimi RM, Rosner B, Xu X, Ziegler R, Eliassen AH. Caffeine, coffee, and tea intake and urinary estrogens and estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1174-83. doi: 10.1158/1055-9965.EPI-15-0246. Epub 2015 Jun 10. PMID: 26063478; PMCID: PMC4526325.
[11.] Smith AJ, Phipps WR, Thomas W, Schmitz KH, Kurzer MS. The effects of aerobic exercise on estrogen metabolism in healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):756-64. doi: 10.1158/1055-9965.EPI-12-1325. PMID: 23652373; PMCID: PMC3648856.
[12.] Teranishi M, Kashihara M, Fujii Y. Selective synthesis of 4-methoxyestrogen from 4-hydroxyestrogen. Steroids. 2001;66(8):615-621. doi:https://doi.org/10.1016/s0039-128x(00)00236-1
[13.] Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 1998;19(1):1-27. doi:https://doi.org/10.1093/carcin/19.1.1